Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings

With the advent of tyrosine kinase inhibitors (TKIs), the treatment prospects of chronic myeloid leukemia (CML) have changed markedly. This innovation can lengthen the long-term survival of patients suffering from CML. However, long-term exposure to TKIs is accompanied by various adverse events (AEs...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Fang, Li, Qiang, Cui, Zheng, Hong, Mei, Li, Weiming, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113500/
https://www.ncbi.nlm.nih.gov/pubmed/37091188
http://dx.doi.org/10.3389/fonc.2023.1146108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113500/
https://www.ncbi.nlm.nih.gov/pubmed/37091188
http://dx.doi.org/10.3389/fonc.2023.1146108

Ejemplares similares